Phospho-BCL2L11 (S59) Antibody

What is BCL2L11 and why is the S59 phosphorylation site important?

BCL2L11 (also known as Bim) belongs to the BCL-2 protein family and contains a Bcl-2 homology domain 3 (BH3). It functions as a pro-apoptotic regulator involved in various cellular activities, particularly in neuronal and lymphocyte apoptosis. Bim can be induced by nerve growth factor (NGF) and the forkhead transcription factor FKHR-L1 .

The S59 phosphorylation site is critically important because:

• It affects Bim's ability to stabilize anti-apoptotic protein Mcl-1

• Phosphorylation at this site alters Bim's binding preferences among different BCL-2 family proteins

• It modulates Bim's pro-apoptotic functions within signaling pathways

What are the recommended applications for Phospho-BCL2L11 (S59) Antibody?

Based on validated research applications, Phospho-BCL2L11 (S59) antibodies are suitable for:

• Immunohistochemistry (IHC): Recommended dilutions between 1:100-1:300

• Enzyme-Linked Immunosorbent Assay (ELISA): Optimal working dilution of approximately 1:40000

• Western Blotting (WB): While not explicitly validated for all commercial antibodies, this technique is commonly used to detect phosphorylated Bim in experimental settings

For optimal results, researchers should perform antibody titration experiments to determine the ideal concentration for their specific experimental conditions and sample types .

How should Phospho-BCL2L11 (S59) Antibody be stored and handled?

For maximum stability and reactivity:

• Store at -20°C for long-term storage (up to one year)

• For frequent use and short-term storage, keep at 4°C for up to one month

• Avoid repeated freeze-thaw cycles as they can denature the antibody and reduce its effectiveness

• Most commercially available antibodies are supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide

What is the specificity of Phospho-BCL2L11 (S59) Antibody?

Commercial Phospho-BCL2L11 (S59) antibodies:

• Detect endogenous levels of Bim protein only when phosphorylated at S59

• Show reactivity with human, mouse, and rat samples

• Are typically generated using synthesized peptides derived from human Bim around the phosphorylation site of Ser59 (amino acid range: 31-80)

• Have no reported cross-reactivity with other proteins when properly validated

How does S59 phosphorylation affect Bim's interaction with other BCL-2 family proteins?

Phosphorylation at S59 significantly alters Bim's binding preferences and functional interactions with other BCL-2 family proteins:

• Altered Mcl-1 stabilization: In studies using phospho-mimetic mutations, the S59E Bim mutation leads to significantly lower Mcl-1 protein levels compared to wild-type Bim. This effect is posttranscriptional and cell line-dependent .

• Changed binding preferences: When compared to wild-type Bim, the S59E phospho-mimetic mutation results in substantially more Bim bound to Bcl-xL, suggesting that phosphorylation at S59 may redirect Bim's binding from Mcl-1 to Bcl-xL .

• Differential binding affinity: Treatment with the Mcl-1 inhibitor S63845 releases more S59E Bim from Mcl-1 in a dose-dependent fashion compared to wild-type Bim, indicating that S59 phosphorylation alters the binding affinity between Bim and Mcl-1 .

These findings suggest that S59 phosphorylation functions as a molecular switch that redirects Bim's interactions within the apoptotic machinery.

What methods are most effective for studying the functional consequences of S59 phosphorylation?

To investigate the functional impact of S59 phosphorylation on BCL2L11/Bim, researchers have successfully employed these methodological approaches:

• Phospho-mimetic mutations: Creating stable cell lines expressing S59E (glutamate substitution to mimic phosphorylation) or S59A (alanine substitution to prevent phosphorylation) Bim mutants .

• Co-immunoprecipitation (Co-IP): To analyze binding interactions between phosphorylated Bim and other BCL-2 family proteins like Mcl-1 and Bcl-xL .

• Quantitative RT-PCR (qRT-PCR): To confirm that altered protein levels (e.g., of Mcl-1) result from post-transcriptional rather than transcriptional effects .

• Two-dimensional electrophoresis: To analyze phospho-isomer profiles of Bim .

• Targeted mass spectrometry: Systems like SigPath can be used to quantitatively measure phosphorylation at specific sites within a broader phosphoproteomic context .

• Phospho-specific Western blotting: To detect changes in phosphorylation status following various cellular treatments and perturbations .

How can researchers validate the specificity of Phospho-BCL2L11 (S59) Antibody in their experimental system?

To ensure high-quality, reproducible results, validate antibody specificity through these recommended approaches:

• Pre-absorption control: Incubate the antibody with the immunizing phosphopeptide prior to the primary application. This should abolish specific staining/signal if the antibody is truly phospho-specific .

• Phosphatase treatment control: Treat a portion of your samples with lambda phosphatase to remove phosphorylation. A phospho-specific antibody should show reduced or absent signal in these samples.

• Phospho-ELISA validation: Compare antibody reactivity between phosphorylated and non-phosphorylated peptides in an ELISA format to confirm phospho-specificity .

• Genetic controls: Use cells expressing S59A mutant Bim (which cannot be phosphorylated at this site) as a negative control.

• Stimulation experiments: Treat cells with stimuli known to induce or reduce S59 phosphorylation to confirm the antibody can detect dynamic changes in phosphorylation status.

Researchers should be aware of these potential challenges:

• Tissue-specific phosphorylation patterns: The phosphorylation status of Bim at S59 may vary significantly between tissue types and disease states, affecting detection sensitivity .

• Antigen retrieval requirements: For immunohistochemistry applications, high-pressure and high-temperature Tris-EDTA (pH 8.0) antigen retrieval is typically required for optimal results with paraffin-embedded samples .

• Endogenous phosphorylation levels: In some cell types or conditions, basal S59 phosphorylation may be low, making detection challenging without prior enrichment strategies.

• Cross-reactivity with other phosphoproteins: While commercial antibodies claim no cross-reactivity , researchers should still validate this in their specific experimental context.

• Sample preparation effects: Phosphorylation can be lost during sample preparation if phosphatase inhibitors are not included in lysis buffers (recommended components include 20 mM NaF, 1 mM PMSF, and a protease inhibitor cocktail) .

How can mass spectrometry complement antibody-based detection of S59 phosphorylation?

Targeted mass spectrometry approaches provide complementary advantages to antibody-based detection:

• SigPath assay: This highly multiplexed, quantitative mass spectrometry assay can measure 284 phosphosites spanning 200 phosphoproteins simultaneously, allowing researchers to place S59 phosphorylation in broader signaling context .

• Comprehensive phosphosite coverage: Mass spectrometry can detect and quantify multiple phosphorylation sites on Bim simultaneously, providing a more complete picture of its phosphorylation status .

• Absolute quantification: Using heavy-labeled phosphopeptide standards, mass spectrometry can provide absolute quantification of phosphorylation stoichiometry .

• Phosphoproteome-wide analysis: Mass spectrometry allows integration of S59 phosphorylation data with the broader cellular phosphoproteome to identify novel signaling relationships .

For optimal results, researchers should consider using both antibody-based detection methods (for targeted, high-sensitivity applications) and mass spectrometry (for unbiased, multiplexed analysis) in complementary approaches.

What are the best cell models for studying S59 phosphorylation of BCL2L11/Bim?

Based on published research, these cell models have proven useful for investigating S59 phosphorylation:

• RPCI-WM1 cells: This cell line shows constitutive phosphorylation of Bim and has been successfully used to study the effects of various phosphorylation sites, including S59, on Mcl-1 stabilization .

• 293T cells: These cells have been used for transient transfection of phospho-mimetic Bim mutants, though they show less Mcl-1 stabilization compared to RPCI-WM1 cells .

• T lymphocytes: Primary T cells have been used to study Bim phosphorylation in response to mitogenic activation with PMA/ionomycin .

• Cancer cell lines with relevant genetic contexts: Cell lines representing various cancer types (lung, B-cell lymphoma, mantle cell lymphoma, prostate, ovarian, bladder, and melanoma) can be selected to maximize detection of endogenous phosphosites .

When selecting a cell model, researchers should consider the endogenous phosphorylation status of Bim, the expression levels of relevant kinases and phosphatases, and the genetic context that might influence Bim-mediated apoptotic signaling.

How can researchers use phospho-specific antibodies to investigate the kinetics of S59 phosphorylation?

To study the dynamic regulation of S59 phosphorylation:

• Time-course experiments: Treat cells with relevant stimuli (e.g., growth factors, stress inducers, kinase inhibitors) and collect samples at multiple time points for Western blot analysis with Phospho-BCL2L11 (S59) antibody.

• Pulse-chase analysis: Label cells with radioactive orthophosphate, immunoprecipitate Bim, and analyze the kinetics of S59 phosphorylation and dephosphorylation.

• Pharmacological inhibitors: Use specific kinase or phosphatase inhibitors to modulate S59 phosphorylation and determine the responsible enzymes.

• Immunofluorescence microscopy: Use phospho-specific antibodies to track the subcellular localization of phosphorylated Bim over time following cellular stimulation.

• Flow cytometry: For cell populations with heterogeneous responses, phospho-flow cytometry can provide single-cell resolution of phosphorylation kinetics.

When designing these experiments, researchers should include appropriate controls, such as total Bim antibody to normalize for changes in protein expression and phospho-deficient mutants (S59A) as negative controls.

How is S59 phosphorylation of BCL2L11/Bim involved in cancer pathogenesis and therapy resistance?

The phosphorylation of Bim at S59 has important implications for cancer biology:

• Apoptotic regulation: Since Bim is a pro-apoptotic protein, its phosphorylation can modulate cancer cell survival and response to therapy by altering its interactions with anti-apoptotic proteins like Mcl-1 .

• Therapeutic resistance: Changes in Bim phosphorylation status may contribute to resistance mechanisms in cancer therapy, particularly in contexts where the balance between pro- and anti-apoptotic proteins is critical for treatment response .

• Targeted therapies: In ALK-fusion cell lines treated with Ceritinib (an ALK inhibitor), significant changes in phosphosignaling networks were observed, which included alterations in BCL-2 family protein phosphorylation . This suggests that monitoring Bim phosphorylation could provide insights into treatment response.

• Bypass mechanisms: After ALK inhibition, increased phosphorylation at activating sites on ERBB2 (Y1248) and ERBB3 (Y1289) was observed, which could represent bypass tracks that can be targeted in resistant disease . Understanding how these changes affect Bim phosphorylation could reveal new therapeutic strategies.

What are the technical considerations for detecting phosphorylated BCL2L11/Bim in clinical samples?

When working with clinical samples, researchers should consider:

• Sample preservation: Phosphorylation can be rapidly lost due to phosphatase activity. Samples should be collected and processed quickly, with immediate fixation or snap-freezing depending on the intended application.

• Fixation methods: For immunohistochemistry, formalin fixation can affect phosphoepitope detection. Optimization of antigen retrieval methods is critical, with Tris-EDTA (pH 8.0) under high-pressure and high-temperature conditions recommended for Phospho-BCL2L11 (S59) antibody .

• Phosphatase inhibitors: Include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) in all buffers used for tissue homogenization and protein extraction.

• Normalization strategy: Use total Bim antibodies in parallel to normalize phospho-signal to total protein levels, accounting for variations in Bim expression between samples.

• Validation controls: Include phosphatase-treated control samples to confirm signal specificity, and consider using samples with known phosphorylation status as positive and negative controls.

• Complementary approaches: Combine antibody-based detection with mass spectrometry-based approaches for comprehensive phosphorylation profiling in clinical samples .

How do different kinase pathways regulate S59 phosphorylation of BCL2L11/Bim?

While the kinases directly responsible for S59 phosphorylation are not fully characterized in the provided search results, we can infer potential regulatory pathways:

• ERK pathway: Though better characterized for S69/S65 phosphorylation, the ERK pathway may also influence S59 phosphorylation, as suggested by studies using ERK pathway inhibitors (U0126) .

• Integration with other signaling pathways: The SigPath phosphoproteomics assay has revealed interconnections between multiple signaling pathways, including EGFR and FGFR pathways, which could potentially regulate Bim phosphorylation .

• ALK signaling: In ALK-fusion cell lines, ALK inhibition leads to significant changes in phosphosignaling networks , which could include alterations in Bim phosphorylation.

• β1 integrin signaling: Studies on P311 phosphorylation at S59 have shown connections to β1 integrin signaling , suggesting potential cross-talk with Bim phosphorylation at the same site.

To definitively identify the kinases responsible for S59 phosphorylation, researchers should consider:

• Kinase inhibitor screening

• In vitro kinase assays with purified kinases

• siRNA/shRNA knockdown of candidate kinases

• Phosphoproteomics analysis before and after kinase inhibition

How can researchers distinguish between the effects of phosphorylation at S59 and other post-translational modifications of BCL2L11/Bim?

To differentiate the specific effects of S59 phosphorylation from other modifications:

• Site-specific mutants: Generate and compare the effects of individual phosphosite mutants (e.g., S59A, S69A) and combination mutants to dissect site-specific functions .

• Phospho-mimetic approach: Use phospho-mimetic mutations (e.g., S59E) to simulate constitutive phosphorylation at specific sites while preventing phosphorylation at others .

• Phospho-specific antibodies: Use antibodies that specifically recognize different phosphorylated forms of Bim (e.g., pS59, pS69/pS65) in parallel experiments .

• Mass spectrometry-based approaches: Employ targeted mass spectrometry to simultaneously quantify multiple phosphorylation sites and their stoichiometry .

• Functional readouts: Assess different functional outcomes (e.g., Mcl-1 binding, Bcl-xL binding, apoptosis induction) that may be specifically regulated by distinct phosphorylation events .

• Kinase/phosphatase manipulation: Use specific kinase activators or inhibitors to selectively modulate phosphorylation at particular sites based on known kinase preferences.

What are the emerging technologies for studying S59 phosphorylation dynamics?

Cutting-edge approaches for investigating Bim phosphorylation include:

• SigPath and targeted MS assays: These highly multiplexed, quantitative mass spectrometry assays can measure hundreds of phosphosites simultaneously, providing comprehensive phosphorylation profiles .

• Phospho-proteomic network analysis: Integration of phosphorylation data into signaling network models to understand how S59 phosphorylation fits within broader cellular signaling contexts .

• CRISPR-Cas9 genome editing: Generation of endogenous phospho-deficient or phospho-mimetic mutations to study physiological consequences without overexpression artifacts.

• Single-cell phospho-proteomics: Analysis of phosphorylation heterogeneity at the single-cell level to understand cell-to-cell variability in Bim regulation.

• Proximity labeling approaches: Methods like BioID or TurboID can identify proteins that interact specifically with phosphorylated or non-phosphorylated forms of Bim.

• Phosphorylation biosensors: Development of FRET-based biosensors to monitor S59 phosphorylation dynamics in live cells in real-time.

How might combination therapies targeting BCL2L11/Bim phosphorylation improve cancer treatment outcomes?

Based on current understanding of Bim phosphorylation:

• Combination with BH3 mimetics: Since S59 phosphorylation affects Bim's interactions with anti-apoptotic proteins like Mcl-1 , combining kinase inhibitors that modulate S59 phosphorylation with BH3 mimetics (e.g., S63845 for Mcl-1, venetoclax for Bcl-2) could enhance therapeutic efficacy.

• Dual targeting of survival pathways: Targeting both the kinases responsible for S59 phosphorylation and downstream survival pathways could prevent compensatory resistance mechanisms .

• Personalized therapy approaches: Analysis of patient tumor samples for Bim phosphorylation status could guide selection of targeted therapies based on individual phosphosignaling profiles .

• Combination with immunotherapy: Understanding how Bim phosphorylation affects immune cell apoptosis could inform strategies to combine kinase inhibitors with immune checkpoint blockade.

• Sequential therapy scheduling: Knowledge of the dynamics of S59 phosphorylation following initial therapy could guide optimal timing for sequential treatment approaches to overcome adaptive resistance.